Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer, September 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 222 articles: HTML format

Single Articles

1. CONTIERI R, Hurle R
   Reply to Francesco Di Bello, Andrea Gallioli, Joan Palou, and Alberto Breda's Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients
   Eur Urol Oncol. 2026 Sep 5:S2588-9311(26)00240-3. doi: 10.1016/j.euo.2026.
   PubMed    
   
   
   

2. CHEN Z, Li J, Hu H, Zhang Y, et al
   Biocompatible HA-PBA/PVA Dual-Network Hydrogel Composite System: A Promising Localized Therapeutic Platform for Bladder Cancer.
   ACS Appl Bio Mater. 2026 Sep 4. doi: 10.1021/acsabm.6c01346.
   PubMed    
   Abstract available
   
   

3. SHENG Z, Zhu J, Sun J, Zeng S, et al
   Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential.
   Front Cell Infect Microbiol. 2026;16:1890640.
   PubMed    
   Abstract available
   
   

4. ITO W, Tachibana I
   Biomarker-guided selection of intravesical therapy in high-risk non-muscle invasive bladder cancer: A contemporary review.
   Ther Adv Urol. 2026;18:17562872261485770.
   PubMed    
   Abstract available
   
   

5. KRUITHOF-DEJULIO M
   Editor's corner: Heavy metal exposure and the epigenetic landscape of urothelial bladder cancer.
   Gene. 2026 Sep 3:150377. doi: 10.1016/j.gene.2026.150377.
   PubMed    
   
   
   

6. WANG Q, Wang D, Jiang H, Min J, et al
   Cancer-associated fibroblasts-derived CAV1 promotes epithelial-mesenchymal transition and stemness in bladder cancer through activation of the LIF/STAT3 signaling pathway.
   Transl Oncol. 2026;73:103001.
   PubMed    
   Abstract available
   
   

7. SHAH KU, Jaime-Casas S, Agarwal R, Zhang G, et al
   Regional Variation in Bladder Cancer Clinical Trial Availability in the US.
   JAMA Netw Open. 2026;9:e2632012.
   PubMed    
   Abstract available
   
   

8. TAN S, Nie C, Yang S, Dai C, et al
   Sexual life and intimate relationship experience among bladder cancer patients: a systematic review and qualitative meta-synthesis.
   Front Public Health. 2026;14:1887122.
   PubMed    
   Abstract available
   
   

9. NAKAYASU R, Hamada A, Sakatani T, Mizuno K, et al
   Adverse event-related discontinuation of maintenance Bacillus Calmette-Guerin therapy and oncological outcomes in non-muscle-invasive bladder cancer.
   Int J Clin Oncol. 2026 Sep 2. doi: 10.1007/s10147-026-03179.
   PubMed    
   Abstract available
   
   

10. FIZ F, Bottoni G, Boitano M, Ugolini M, et al
    [(64)Cu]CuCl(2) as a Novel Metabolic Marker of Progression and Survival in Muscle-Invasive Bladder Cancer.
    Mol Imaging Biol. 2026 Sep 2. doi: 10.1007/s11307-026-02135.
    PubMed    
    Abstract available
    
    

11. OBMANN MM
    Low-keV Reconstructions, No Extra Scan: Photon-Counting CT's Case for Bladder Cancer Local Staging.
    AJR Am J Roentgenol. 2026 Sep 2. doi: 10.2214/AJR.26.35798.
    PubMed    
    
    
    

12. KORKES F, Galdino M, Burger H, Archila D, et al
    Conversion From Cutaneous Ureterostomy to Ileal Conduit in Frail Patients: A Descriptive Case Series.
    Arch Esp Urol. 2026;79:1264-1268.
    PubMed    
    Abstract available
    
    

13. LEE HW, Song G, Lee HH, Jung EH, et al
    Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial.
    Investig Clin Urol. 2026;67:441-451.
    PubMed    
    Abstract available
    
    

14. COSTA TM, Demartino G, de Toledo LGM, Vetorazzi GD, et al
    Intravesical gemcitabine versus Bacillus Calmette-Guerin (BCG) for intermediate-/high-risk non-muscle-invasive bladder cancer during the BCG shortage: Safety, efficacy, and health-economic context.
    Investig Clin Urol. 2026;67:431-440.
    PubMed    
    Abstract available
    
    

15. HERVER VAZQUEZ ME, Mora Montoya MJ, Coria Dominguez LA, Granados Sanchez EF, et al
    Radiotherapy for Metastatic Bladder Cancer in the Era of Modern Systemic Therapies.
    Cureus. 2026;18:e113796.
    PubMed    
    Abstract available
    
    

16. XIAO Y, Zhang X, Xie Z, Tao L, et al
    Potential of RAD51C as a hub gene and therapeutic target in bladder cancer: insights from bioinformatics and experimental analysis.
    Int J Surg. 2026;112:13049-13072.
    PubMed    
    Abstract available
    
    

17. LIU S, Wang Y, Peng S, Wang J, et al
    RUNX3+ basal-like malignant cells: architects of an immunosuppressive microenvironment in bladder cancer: a comprehensive bioinformatics analysis of single-cell and spatial transcriptomics.
    Int J Surg. 2026;112:13034-13048.
    PubMed    
    Abstract available
    
    

18. ZHANG Q, Zhao N, Song K, Ye X, et al
    SurvGRN: a multi-feature fusion framework for bladder cancer survival prediction.
    Int J Surg. 2026;112:13092-13104.
    PubMed    
    Abstract available
    
    

19. DOWNES MR, Wobker SE, Smith SC, Eckstein M, et al
    International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer: Working Group 2: The Urinary Bladder.
    Am J Surg Pathol. 2026 Sep 2. doi: 10.1097/PAS.0000000000002613.
    PubMed    
    Abstract available
    
    

20. MANIVASAGAM SS, Clark JY, Raman JD
    Unintended consequences of antibiotic practices: the relationship between bowel preparation, prolonged prophylaxis, and ileus after radical cystectomy.
    Can J Urol. 2026;33:865-871.
    PubMed    
    Abstract available
    
    

21. KHALID U, Shah N, Kavia R, Batura D, et al
    Artificial intelligence advances in cystoscopy and imaging for bladder cancer: a narrative review.
    Can J Urol. 2026;33:735-752.
    PubMed    
    Abstract available
    
    

22. RICHTMANN S, Radak M, Sincic V, Hugoson J, et al
    Bladder cancer precision-cut tumor slices (PCTS) preserve functional immune microenvironment enabling ex vivo drug evaluation.
    BMC Med. 2026;24:468.
    PubMed    
    Abstract available
    
    

23. ODAGIRI K, Morikawa T, Naiki T, Sugiyama Y, et al
    Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.
    Cancer Med. 2026;15:e72252.
    PubMed    
    Abstract available
    
    

24. MAEDA S, Yokota S, Komori M, Goto-Koshino Y, et al
    Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.
    Sci Rep. 2026;16:24028.
    PubMed    
    Abstract available
    
    

25. SILCOCK L, Hastings RK, Clokie S, Sadler R, et al
    Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics.
    Eur Urol Oncol. 2026 Sep 2:S2588-9311(26)00233-6. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available
    
    

26. LIU K, Xu F, Wu C, Wang M, et al
    Mechanisms of resistance to antibody-drug conjugates in bladder cancer.
    Front Pharmacol. 2026;17:1882868.
    PubMed    
    Abstract available
    
    

27. PERICART S, Tosolini M, Roumiguie M, Saint A, et al
    A High Density of Impaired Tertiary Lymphoid Structures Is Associated with Higher Tumor Stage and Recurrence in Non-Muscle-Invasive Bladder Cancer.
    Cancer Immunol Res. 2026 Aug 31. doi: 10.1158/2326-6066.CIR-26-0104.
    PubMed    
    Abstract available
    
    

28. OSKA C, Mehta KJ, Simone CB 2nd, Hsieh K, et al
    Proton Therapy for Muscle-Invasive Bladder Cancer: Outcomes from the Multicenter Proton Collaborative Group PCG 001-09 Registry Trial.
    Cureus. 2026;18:e113689.
    PubMed    
    Abstract available
    
    

29. YUAN Q, Song T, He Y, Xia S, et al
    AARS1-Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer.
    Adv Sci (Weinh). 2026 Aug 30:e77479. doi: 10.1002/advs.77479.
    PubMed    
    Abstract available
    
    

30. CHO WC
    Enhanced CT-based deep learning radiomics for bladder cancer prognosis.
    Mil Med Res. 2026;13:100065.
    PubMed    
    
    
    

31. CAO Q, Liu H, Xu Y, Wang Y, et al
    Using human proteomic and lipidomic to exploration drug target of bladder cancer.
    World J Urol. 2026;44:619.
    PubMed    
    Abstract available
    
    

32. KIVANC D, Erdem S, Hurdogan O, Ciftci HS, et al
    The effect of toll like receptors in prognosis in patients undergoing radical cystectomy for bladder cancer.
    Mol Biol Rep. 2026;53:1489.
    PubMed    
    Abstract available
    
    

33. WILLIAMS C, Shah Y, Xia L
    Perioperative treatment for muscle invasive bladder cancer in the era of immunotherapy.
    Ther Adv Urol. 2026;18:17562872261481954.
    PubMed    
    Abstract available
    
    

34. ZHAO M, Wu Y, Luo B, Long J, et al
    Prognostic value of preoperative systemic immune-inflammation index in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1909255.
    PubMed    
    Abstract available
    
    

35. ZHOU FY, Wang J, Xu R, Yang LW, et al
    Smart nanoplatform based on mesoporous polydopamine for combined photothermal-chemotherapy in the treatment of urothelial carcinoma.
    Colloids Surf B Biointerfaces. 2026;268.
    PubMed    
    Abstract available
    
    

36. DEHGHANPOUR A, Pecoraro M, Zhang GM, Borrelli A, et al
    VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification.
    Eur Urol Oncol. 2026;9:930-937.
    PubMed    
    Abstract available
    
    

37. COMPERAT EM, Hartmann A, Allory Y, Bellosillo B, et al
    FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting.
    Eur Urol Oncol. 2026;9:977-985.
    PubMed    
    Abstract available
    
    

38. TERAUCHI T, Nguyen TT, Takata M, Shimizu R, et al
    Clinical and Cytopathological Significance of Intracytoplasmic Lumina and Immunohistochemical Mucin Expression in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Diagn Cytopathol. 2026;54:764-772.
    PubMed    
    Abstract available
    
    

39. DILLON R, Jones R, Flechon A, Chan K, et al
    Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy +/- Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.
    Eur Urol Oncol. 2026;9:938-945.
    PubMed    
    Abstract available
    
    

40. UZUN E, Ozen S, Senel S, Arabaci HB, et al
    Variant histology in urothelial carcinoma: associated factors and survival impact after radical cystectomy.
    BMC Urol. 2026;26:213.
    PubMed    
    Abstract available
    
    

41. MAIORANO BA, Roviello G, Rizzo A, Ciccimarra F, et al
    Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.
    Sci Rep. 2026;16:27711.
    PubMed    
    Abstract available
    
    

42. SAO LEAO RIBEIRO LC, Araujo Matalani CF, Vilares RN, Suartz CV, et al
    Neoplasms in prune belly syndrome: A novel case of early-onset metastatic bladder carcinoma and systematic review of reported tumors.
    J Pediatr Urol. 2026;22:106048.
    PubMed    
    Abstract available
    
    

43. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
    Improving long-term monitoring in NMIBC: Digital Uromonitor(R) (dUM) as a complementary tool to cystoscopy for two-year recurrence risk stratification.
    Actas Urol Esp (Engl Ed). 2026;50:501994.
    PubMed    
    Abstract available
    
    

44. GONTERO P, Soria F, Babjuk M, Burger M, et al
    Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.
    Eur Urol Oncol. 2026;9:868-882.
    PubMed    
    Abstract available
    
    

45. AYDIN YM, Ozdel O, Mungan NA
    Clinical and tumor-related determinants of early morbidity and prolonged hospital stay after TUR-BT.
    Actas Urol Esp (Engl Ed). 2026;50:501987.
    PubMed    
    Abstract available
    
    

46. CORBETT MP, Elbadawy M, Woodward AP, Cheville JC, et al
    Histologic and immunohistochemical characterization and frequency of rare subtypes of canine invasive urothelial carcinoma.
    Vet Pathol. 2026;63:807-819.
    PubMed    
    Abstract available
    
    

47. LI C, Hu Z, Zhang W, Ji Y, et al
    Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications.
    Nat Rev Urol. 2026;23:607-620.
    PubMed    
    Abstract available
    
    

48. PFISTER C, Harter V, Fontugne J, Allory Y, et al
    Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor.
    Eur Urol Oncol. 2026;9:795-803.
    PubMed    
    Abstract available
    
    

49. TEOH JY, Wong CH, Cheng CH, Tsang CF, et al
    Impact of Intravesical Bacillus Calmette-Guerin Therapy Following Transurethral En Bloc Resection of Bladder Tumour: Post Hoc Analysis of a Randomised, Multicentre, Phase 3 Trial.
    Eur Urol Oncol. 2026;9:761-765.
    PubMed    
    Abstract available
    
    

50. ZHANG B, Zhu J, Hong Z, Wang Y, et al
    An engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy.
    Mater Today Bio. 2026;40:103593.
    PubMed    
    Abstract available
    
    

51. HE Y, Lu W, Ju G, Chen L, et al
    Single-cell transcriptomics deciphers cancer-associated fibroblast heterogeneity and immune regulatory mechanisms in the bladder cancer tumor microenvironment.
    Front Cell Dev Biol. 2026;14:1889050.
    PubMed    
    Abstract available
    
    

52. HE J, Zhao J, Luo Y, Li M, et al
    Integrated bioinformatics analyses for GSDMB in carcinogenesis and progression of bladder cancer.
    Transl Androl Urol. 2026;15:295.
    PubMed    
    Abstract available
    
    

53. GILFRICH C, Kravchuk A, Rinderknecht E, Haas M, et al
    Beyond staging: toward a layered risk architecture after radical cystectomy for bladder cancer.
    Transl Androl Urol. 2026;15:260.
    PubMed    
    
    
    

54. ZHOU J, Geng J, Qiu H, Guo J, et al
    Multi-omics integration identifies HSPA4 as a therapeutic target and reveals DON-induced endoplasmic reticulum stress in bladder cancer.
    Transl Androl Urol. 2026;15:262.
    PubMed    
    Abstract available
    
    

55. CAO J, Yang J, Shang W, Tan H, et al
    Integrated transcriptome analysis and machine learning to construct a homeostatic model of acetylation for bladder cancer and validate the key gene CES1.
    Transl Androl Urol. 2026;15:271.
    PubMed    
    Abstract available
    
    

56. PEAT N, Jones GD, Veal I, Kinsella N, et al
    Physical activity in advanced urological cancers undergoing immune checkpoint inhibitor treatment: a qualitative study exploring patient perspectives and experiences.
    Support Care Cancer. 2026;34:963.
    PubMed    
    Abstract available
    
    

57. MATSUSHITA Y, Taguchi S, Naiki T, Ishikawa G, et al
    Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma.
    World J Urol. 2026;44:657.
    PubMed    
    Abstract available
    
    

58. AHMADI P, Deyhimfar R, Haghani I, Mohammadi A, et al
    Corrigendum to "Citalopram enhances cisplatin-induced cytotoxicity in T24 bladder cancer cells: An in vitro study" [Exp. Mol. Pathol. 147 (2026) 105056].
    Exp Mol Pathol. 2026 Sep 11:105074. doi: 10.1016/j.yexmp.2026.105074.
    PubMed    
    
    
    

59. NOZAKI M, Nakagawa R, Kadono Y, Koketsu Y, et al
    Incidental bladder cancer detected by routine cystoscopy before robot-assisted radical prostatectomy: A multicenter retrospective study.
    Urol Oncol. 2026 Sep 11:S1078-1439(26)00709.
    PubMed    
    Abstract available
    
    

60. AHMAD B, Malik A, Brown P, Kumar A, et al
    Vesicocutaneous fistula secondary to invasive bladder squamous cell carcinoma: an unusual initial presentation.
    BMJ Case Rep. 2026;19:e269395.
    PubMed    
    Abstract available
    
    

61. RANJHA FR, Rashid A, Adnan A, Kashif M, et al
    Treatment Patterns and Long-Term Survival Outcomes in Muscle-Invasive Bladder Cancer: A Decade-Long Single-Institution Retrospective Cohort Study.
    J Cancer Allied Spec. 2026;12:122-128.
    PubMed    
    Abstract available
    
    

62. SARFRAZ M, Qureshi E, Irfan O, Rashid A, et al
    Asymptomatic bilateral renal granulomas following intravesical BCG immunotherapy for bladder cancer: a case report.
    Ann Med Surg (Lond). 2026;88:5962-5965.
    PubMed    
    Abstract available
    
    

63. KAMENETSKY ME, Koutros S, Spaur M, Kim SD, et al
    Associations between a mixture of trace elements and bladder cancer occurrence: A study of possible reverse causation.
    Environ Epidemiol. 2026;10:e525.
    PubMed    
    Abstract available
    
    

64. 
    Retraction: Long non-coding RNA MEG3 functions as a competing endogenous RNA of miR-93 to regulate bladder cancer progression via PI3K/AKT/mTOR pathway.
    Transl Cancer Res. 2026;15:675.
    PubMed    
    Abstract available
    
    

65. KAWAHARA T, Nishiyama H
    [Evolving Role of Perioperative Immune Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2026;53:507-511.
    PubMed    
    Abstract available
    
    

66. ZHANG Z, Han L, Jia D, Wei Y, et al
    MRICombo: a deep-learning-based framework for universal volumetric segmentation grading-staging and malignancy detection across heterogeneous MRI.
    Nat Commun. 2026;17:9715.
    PubMed    
    Abstract available
    
    

67. WANG J
    Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival.
    Urol Oncol. 2026 Sep 10:S1078-1439(26)00714.
    PubMed    
    
    
    

68. YI H, Han Y, Wang X, Li Q, et al
    IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m(6)A-modified CENPA mRNA.
    Med Oncol. 2026;43:278.
    PubMed    
    Abstract available
    
    

69. MUKHERJEE S, Karati D, Sarkar S, Ash D, et al
    CRISPR-Cas9?based lipid nanocarriers for advanced therapy of urinary bladder cancer.
    Nanomedicine (Lond). 2026 Sep 10:1-11. doi: 10.1080/17435889.2026.2732014.
    PubMed    
    Abstract available
    
    

70. XU J, Huang Q, Deng G, Ye Y, et al
    A Novel Technique of Traction Pre-Bladder Suturing in Single-Position Robot-Assisted Nephroureterectomy: Simplifying the Management of the Intramural Ureter.
    Int J Med Robot. 2026;22:e70230.
    PubMed    
    Abstract available
    
    

71. XU JL, Fan CQ, Peng YQ, Yang XT, et al
    Factors Associated With Self-Perceived Burden and Its Relationship With Quality of Life Among Patients With Bladder Cancer Undergoing Ileal Conduit Urinary Diversion: A Cross-Sectional Study.
    Cancer Med. 2026;15:e72253.
    PubMed    
    Abstract available
    
    

72. DUQUESNE I, Chakra MA, de la Taille A, O'Donnell MA, et al
    Risk Stratification in Non-Muscle-Invasive Bladder Cancer in the Era of Expanding Therapeutic Options: Are Current Classifications Still Adequate?
    Fr J Urol. 2026 Sep 9:103200. doi: 10.1016/j.fjurol.2026.103200.
    PubMed    
    Abstract available
    
    

73. MITRAKAS L, Zisopoulos A, Dimitropoulos K, Siafakas S, et al
    Introducing "HEDGE": sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) plus docetaxel as a potential novel bladder-sparing strategy for BCG-unresponsive non-muscle-invasive bladder cancer.
    Arch Ital Urol Androl. 2026 Sep 9:15738. doi: 10.4081/aiua.2026.15738.
    PubMed    
    Abstract available
    
    

74. PAN S, Xu W, Xiang Y, Huang M, et al
    Overcoming barriers to bladder preservation: Emerging intravesical therapies for high-risk non-muscle-invasive bladder cancer.
    Chin J Cancer Res. 2026;38:411-430.
    PubMed    
    Abstract available
    
    

75. HUANG F, Chen C, Mao Y, Lin T, et al
    Prognostic effect of the preoperative albumin-to-globulin ratio bladder cancer: a meta-analysis.
    Front Med (Lausanne). 2026;13:1848522.
    PubMed    
    Abstract available
    
    

76. NOSSING C, Prantl I, Grausenburger R, Ertl IE, et al
    Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer.
    Eur Urol Oncol. 2026 Sep 8:S2588-9311(26)00232-4. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available
    
    

77. MERCADER C, Ingelmo-Torres M, Roldan FL, Figueras M, et al
    Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck.
    Cancer Cytopathol. 2026;134:e70141.
    PubMed    
    Abstract available
    
    

78. CAMARGO JA, Lee MC, Souza MM, Silva LPD, et al
    MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model.
    IUBMB Life. 2026;78:e70130.
    PubMed    
    Abstract available
    
    

79. PROKUNINA-OLSSON L, Florez-Vargas O, Levin MG, Dutta D, et al
    Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk.
    Nat Commun. 2026;17:9591.
    PubMed    
    Abstract available
    
    

80. EATON D, Kerdemelidis M, Losco G, Mark S, et al
    Cxbladder Triage in Haematuria Assessment Reduces Time From Referral to Specialist Assessment and Bladder Cancer Treatment and Improves Equity for Maori.
    ANZ J Surg. 2026 Sep 7. doi: 10.1111/ans.70960.
    PubMed    
    Abstract available
    
    

81. WANG L, Yang J, Wan S, Li K, et al
    PRDX1 facilitates USP7-dependent stabilization of SCD1 and promotes bladder cancer progression.
    Cell Signal. 2026;149:112882.
    PubMed    
    Abstract available
    
    

82. KAWASAKI JAI, de Souza AP, Pontes JPR, Serpeloni JM, et al
    Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma.
    Mol Biol Rep. 2026;53:1544.
    PubMed    
    Abstract available
    
    

83. AZIZ MN, Wang T, Lang J, Glover M, et al
    Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer.
    Mol Pharm. 2026;23:4758-4769.
    PubMed    
    Abstract available
    
    

84. RIBEIRO-PEREIRA R, Teixeira-Marques A, Freitas R, Carvalho JA, et al
    Predictive and prognostic biomarkers of Bacillus Calmette-Guerin therapy failure in bladder cancer patients: A systematic review.
    Mol Oncol. 2026 Sep 7:10.1002/1878-0261.70329. doi: 10.1002/1878-0261.70329.
    PubMed    
    Abstract available
    
    

85. LI J, Xue Y, Guo Z, Ye S, et al
    [Advances in intravesical therapy for non-muscle-invasive bladder cancer].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2026;51:1288-1296.
    PubMed    
    Abstract available
    
    

86. OKUMURA G, Yajima S, Ikezoe E, Gozu S, et al
    Treatment Selection and Survival In Muscle-Invasive Bladder Cancer: Real-World Data on the Impact of Geriatric-8 Screening.
    J Surg Oncol. 2026 Sep 6. doi: 10.1002/jso.70399.
    PubMed    
    Abstract available
    
    

87. ARYA R, Mohapatra AK
    Comment on "A molecular landscape tracking the progression of non-muscle invasive bladder cancer".
    World J Urol. 2026;44:645.
    PubMed    
    
    
    

88. MATSUMURA N
    PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin can
    Int J Clin Oncol. 2026 Sep 6. doi: 10.1007/s10147-026-03190.
    PubMed    
    
    
    

89. CORVINO R, Basile G, Santarelli V, Asero V, et al
    Perioperative and survival outcomes of synchronous vs. metachronous upper tract urothelial carcinoma among bladder cancer patients treated with radical cystectomy and nephroureterectomy: Results from an International Multicenter Collaborative Study-On
    Urol Oncol. 2026 Sep 5:S1078-1439(26)00699-X. doi: 10.1016/j.urolonc.2026.
    PubMed    
    Abstract available
    
    

90. LI X, Su M, Luo J, Han D, et al
    FOXD1 upregulates DARS2-mediated glycolysis to drive cisplatin resistance in bladder cancer.
    Urol Oncol. 2026 Sep 5:S1078-1439(26)00619-8. doi: 10.1016/j.urolonc.2026.
    PubMed    
    Abstract available
    
    

91. ZHOU R, Zhang W, Xia M, Zhang K, et al
    Pentachlorophenol enhances bladder cancer cell invasion through altered protein stability.
    iScience. 2026;29:117357.
    PubMed    
    Abstract available
    
    

92. GAKIS G, Vom Dorp F
    [Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].
    Urologie. 2026 Sep 4. doi: 10.1007/s00120-026-02922.
    PubMed    
    Abstract available
    
    

93. GABRIELSON AT, Grabski DF, Lautz TB, Gong EM, et al
    Modern management and multidisciplinary care of bladder prostate rhabdomyosarcoma.
    Curr Opin Pediatr. 2026;38:531-537.
    PubMed    
    Abstract available
    
    

94. YUGUCHI S, Okubo Y, Kasajima R, Nakaigawa N, et al
    Determinants of nucleic acid quality in formalin-fixed paraffin-embedded bladder urothelial carcinoma specimens: effects of specimen type, fixation conditions, and storage time.
    Ann Diagn Pathol. 2026;85:152681.
    PubMed    
    Abstract available
    
    

95. WANG H, Liu H, Li Q, Sun F, et al
    Exploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validation.
    Clin Exp Med. 2026;26:324.
    PubMed    
    Abstract available
    
    

96. SALHI Y, Makrodimitris S, van Wilpe S, Te Paske I, et al
    Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer.
    Mol Oncol. 2026;20:2175-2187.
    PubMed    
    Abstract available
    
    

97. KANAGAWA T, Yonese I, Nakamura T, Shimizu M, et al
    Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma.
    Jpn J Clin Oncol. 2026;56:1103-1110.
    PubMed    
    Abstract available
    
    

98. ISMAIL FB, Wahid MIA, Thiagarajan M, Tan AL, et al
    Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Real-World Results From an Early Access Program in Malaysia.
    Asia Pac J Clin Oncol. 2026;22:744-748.
    PubMed    
    Abstract available
    
    

99. NAKAGAWA R, Naito R, Izumi K, Inaba T, et al
    Real-World Efficacy of Postoperative Adjuvant Nivolumab in High-Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population.
    Asia Pac J Clin Oncol. 2026;22:685-691.
    PubMed    
    Abstract available
    
    

100. DE ANGELIS M, Siech C, Jannello LMI, Di Bello F, et al
     Does Race/Ethnicity Affect Secondary Bladder and Rectal Cancer Rates After Prostate Cancer Radiation? Results from a Population-Based Study.
     J Racial Ethn Health Disparities. 2026;13:3888-3896.
     PubMed    
     Abstract available
     
     

101. HAN P, Yang X, Li Q, Lu P, et al
     From hematuria warning to precision immunotherapy: an AI-assisted cross-platform analysis of bladder cancer information on social media.
     Front Med (Lausanne). 2026;13:1910134.
     PubMed    
     Abstract available
     
     

102. ZHUANG J, Xie Y, Chen Y, Zheng W, et al
     Radiomics and Deep Learning Models Based on Manual and Semi-automatic Segmentation of Ultrasound Images for HER2 Prediction in Bladder Cancer.
     Acad Radiol. 2026 Sep 18:S1076-6332(26)00715-4. doi: 10.1016/j.acra.2026.
     PubMed    
     Abstract available
     
     

103. GONG M, Shang P
     Comment on "Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice".
     Urol Oncol. 2026;44:725-726.
     PubMed    
     
     
     

104. LIU K, Bao H, Li G, Ran W, et al
     Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study.
     Cancer Lett. 2026 Sep 18:218853. doi: 10.1016/j.canlet.2026.218853.
     PubMed    
     Abstract available
     
     

105. WAN W, Wei F, Yang L, Yu X, et al
     AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer.
     Biochem Pharmacol. 2026 Sep 18:118486. doi: 10.1016/j.bcp.2026.118486.
     PubMed    
     Abstract available
     
     

106. LI J, Chen K, Zhang S, Shen Y, et al
     Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen.
     Urol Oncol. 2026;44:873-886.
     PubMed    
     Abstract available
     
     

107. QU W, Zhu J, Yang Y, Nie F, et al
     Diagnostic value of CEUS-VI-RADS for predicting muscle invasion in bladder cancer: Validation of the scoring system and introduction of tumor-bladder wall contact length as a supplementary quantitative metric.
     Urol Oncol. 2026;44:859-865.
     PubMed    
     Abstract available
     
     

108. CHEN H, Ji S, Wu P, Liu J, et al
     Pyrroline-5-carboxylate reductase 1 interacts with Nudix hydrolase 5 to drive bladder cancer malignant progression via activation of the APOE/JAK2/STAT3 signalling axis.
     Clin Transl Med. 2026;16:e70840.
     PubMed    
     Abstract available
     
     

109. CICVARIC A, Glavas Tahtler J, Pavlovic O, Dias C, et al
     Perioperative cognitive dysfunction in bladder cancer patients, causal factors, and possible interventions.
     Front Med (Lausanne). 2026;13:1883877.
     PubMed    
     Abstract available
     
     

110. HOU Z, Ji M, Peng F, Chen Y, et al
     Case Report: Solitary right thigh skin metastasis of bladder cancer misdiagnosed as erysipelas with literature review.
     Front Oncol. 2026;16:1825362.
     PubMed    
     Abstract available
     
     

111. WAN D, Li Y, Dong Z, Dai C, et al
     Performance evaluation of large language models in bladder cancer patient education Q&A: a cross-sectional study.
     Front Oncol. 2026;16:1909227.
     PubMed    
     Abstract available
     
     

112. SUN J, Wang Z, Yang M, Tan Z, et al
     MRI-derived features reveal recurrence heterogeneity in VI-RADS 2 non-muscle-invasive bladder cancer.
     Front Oncol. 2026;16:1921569.
     PubMed    
     Abstract available
     
     

113. MATHEZ W, Vincentelli A, Chaoui I, Bruyere F, et al
     Antidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis.
     Urologia. 2026 Sep 17:3915603261486088. doi: 10.1177/03915603261486088.
     PubMed    
     Abstract available
     
     

114. BERNDT-PAETZ M, Nurnberger S, Gonsior S, Paczek-Hippe E, et al
     Enhanced survival through repeated photodynamic therapy and almost complete tumor regression by prior radiation therapy in an orthotopic rat bladder cancer model.
     Cancer Cell Int. 2026;26:315.
     PubMed    
     Abstract available
     
     

115. PRAT Y, Mahmud H, Tsur A, Laufer M, et al
     Multimodal large language models for bladder tumor detection in cystoscopy: a retrospective benchmarking study.
     World J Urol. 2026;44:670.
     PubMed    
     Abstract available
     
     

116. BUZOIANU MM, Andras I, Giurgiu L, Medan P, et al
     Preoperative predictors of adverse pathological outcomes following radical cystectomy for muscle-invasive bladder cancer in a tertiary referral center.
     J Med Life. 2026;19:578-582.
     PubMed    
     Abstract available
     
     

117. THALAMBEDU N, Vasipalli K, Sampath Kumar N, Vellanki S, et al
     Immunotherapy role in bladder cancer treatment: a review of literature.
     Front Oncol. 2026;16:1908307.
     PubMed    
     Abstract available
     
     

118. LIU JJ, Sun L, Guo DT, Liang YJ, et al
     Maslinic acid derivative induces the death of transitional bladder cancer cells through apoptosis and autophagy via the PI3K-AKT signaling pathway.
     RSC Med Chem. 2026 Sep 16. doi: 10.1039/d6md00435.
     PubMed    
     Abstract available
     
     

119. FEYISSA M, Baheer Y, Ahmed B, Rosa N, et al
     The use of artificial intelligence and wearable devices in enhanced recovery after surgery pathways following radical cystectomy: A systematic review.
     J Int Med Res. 2026;54:3000605261485388.
     PubMed    
     Abstract available
     
     

120. ITAGI P, Schuster SL, Arora S, Persse TW, et al
     Evolution and heterogeneity of lethal metastatic bladder cancer subtypes.
     Nature. 2026 Sep 16. doi: 10.1038/s41586-026-11035.
     PubMed    
     Abstract available
     
     

121. CONTIERI R, Hurle R
     Reply to Roberto Mario Scarpa's Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer:
     Eur Urol Oncol. 2026 Sep 16:S2588-9311(26)00248.
     PubMed    
     
     
     

122. KAUSHIK R, Pawar D, Sharma A, Siwach K, et al
     Integrated analysis of VEGFA rs833061 (- 460T > C) promoter polymorphism and serum YKL-40 levels in bladder cancer: evidence of a genotype-phenotype association.
     Mol Biol Rep. 2026;53:1585.
     PubMed    
     Abstract available
     
     

123. ZHANG F, Sun B, Guo H
     Risk Factors for Early Postoperative Ileus Following Laparoscopic Radical Cystoprostatectomy.
     J Vis Exp. 2026;.
     PubMed    
     Abstract available
     
     

124. DENG J, Yang B, Wu Z, Wu H, et al
     The burden of bladder cancer and kidney cancer attributable to smoking in Latin America and the Caribbean from 1990 to 2023 and projections to 2050.
     Tob Induc Dis. 2026;24.
     PubMed    
     Abstract available
     
     

125. YU S, Wang Y, Feng D, Dai X, et al
     Multimodal AI and single-cell transcriptomics integrate to construct a histopathological prognostic model for bladder cancer, revealing the RTN3-glycolysis axis in chemoresistance.
     Exp Hematol Oncol. 2026;15:93.
     PubMed    
     Abstract available
     
     

126. LOTAN Y, Raut M, Zhang S, Lai Y, et al
     Real-World Clinical Outcomes Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin: A SEER-Medicare Analysis.
     Clin Genitourin Cancer. 2026 Aug 5:102641. doi: 10.1016/j.clgc.2026.102641.
     PubMed    
     Abstract available
     
     

127. BRANCHER AJ, Brough S, Gallappatige A, Tempo J, et al
     Muscle-invasive urothelial carcinoma of the bladder in a direct inguinal hernia.
     BMJ Case Rep. 2026;19:e270611.
     PubMed    
     Abstract available
     
     

128. BALLAS LK, Solanki AA, Baumann BC, Dirix P, et al
     Radiation Therapy for Bladder Cancer: An ASTRO Clinical Practice Guideline.
     Pract Radiat Oncol. 2026 Sep 15:S1879-8500(26)00273.
     PubMed    
     Abstract available
     
     

129. MASTERS JC, Jermain B, Liu A, Cesari R, et al
     Population Pharmacokinetics and Exposure-Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors.
     J Clin Pharmacol. 2026;66:e70295.
     PubMed    
     Abstract available
     
     

130. FRASLIN AM, Benhamou S, Lebret T, Neuzillet Y, et al
     Longitudinal Economic Burden for Non-Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database.
     Eur Urol Open Sci. 2026;92:28-35.
     PubMed    
     Abstract available
     
     

131. HUANG Y, Ji Y, Yang X, Zhao Q, et al
     Post-Treatment NLR and SII Associations with Response and Progression-Free Survival After Neoadjuvant Disitamab Vedotin Plus PD-1 Blockade in Muscle-Invasive Bladder Cancer: A Real-World Cohort Study.
     Diagnostics (Basel). 2026;16:2802.
     PubMed    
     Abstract available
     
     

132. URRARO F, Giordano N, Patane V, Brunese MC, et al
     The Stalk Sign in Bladder Cancer: CEUS Versus MRI.
     Diagnostics (Basel). 2026;16:2687.
     PubMed    
     Abstract available
     
     

133. ZHANG B, Chang H, Wang C, Chang W, et al
     The MAZ-POLD1 Signaling Axis Drives Cisplatin Resistance in Bladder Cancer by Activating DNA Damage Repair.
     Cancers (Basel). 2026;18:2892.
     PubMed    
     Abstract available
     
     

134. DE MAESENEER D, Decruyenaere A, Van der Meulen J, Loontiens S, et al
     Long-Term Outcomes and Paired Immune and Genomic Exploratory Analyses After Neoadjuvant Dose-Dense MVAC in Muscle-Invasive Bladder Cancer: A Single-Centre Case Series.
     Cancers (Basel). 2026;18:2839.
     PubMed    
     Abstract available
     
     

135. POLITO MG, Sisca L, Caruso D, Cosimati A, et al
     Circulating Tumor DNA in Bladder Cancer: Current Clinical Evidence and Emerging Multi-Omics Perspectives-A Narrative Review.
     Cancers (Basel). 2026;18:2816.
     PubMed    
     Abstract available
     
     

136. LIU Y, Li Z, Kuang Y, Chen K, et al
     1-Hydroxypyrene Promotes Bladder Cancer Progression and Tumor-Associated Immunosuppression via MIF.
     Int J Mol Sci. 2026;27:7778.
     PubMed    
     Abstract available
     
     

137. YU TW, Kawahashi M, Goda F, Kanaya A, et al
     Anti-Tumor Potential of Selective L-Type Amino Acid Transporter (LAT1) Inhibitor, JPH203, in Patient-Derived Canine Bladder Cancer Organoids.
     Int J Mol Sci. 2026;27:7681.
     PubMed    
     Abstract available
     
     

138. CHEN L, Long X, Yang J
     Diosmetin Inhibits Bladder Cancer through Suppression of the PI3K-AKT Signaling Pathway and Activation of the p53 Signal Pathway Revealed by Network Pharmacology and In Vitro Experimental Verification.
     Comb Chem High Throughput Screen. 2026.
     PubMed    
     Abstract available
     
     

139. CHAN L, Anzela A, Do V, Wong K, et al
     Dose-Escalated Radiation Therapy for Muscle-Invasive Bladder Cancer: A Retrospective Analysis.
     Adv Radiat Oncol. 2026;11:102156.
     PubMed    
     Abstract available
     
     

140. UUNK FM, Bosveld J, Boormans JL, van der Heijden AG, et al
     Extended cancer registry data for real-world evidence in bladder cancer: an update on the Prospective Bladder Cancer Infrastructure.
     ESMO Real World Data Digit Oncol. 2026;13:100772.
     PubMed    
     Abstract available
     
     

141. HIROSUNA K, Nishimura K, Sakamoto M, Tokushige S, et al
     Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer.
     Cancer Sci. 2026 Sep 13:10.1111/cas.70534. doi: 10.1111/cas.70534.
     PubMed    
     Abstract available
     
     

142. KULLMANN T, Kerenyi G, Szepesvary Z
     [Improved efficacy of the uro-oncology care in light of the longitudinal patient flow data of a regional center].
     Orv Hetil. 2026;167:1477-1482.
     PubMed    
     Abstract available
     
     

143. SHULMAN MJ, Lee VS, Roh JM, Kwan ML, et al
     Guideline-recommended post-operative intravesical chemotherapy and cystoscopic surveillance among patients with low- and intermediate-risk non-muscle invasive bladder cancer.
     Bladder Cancer. 2026;12:23523735261487765.
     PubMed    
     Abstract available
     
     

144. OLSON DJ, Liu BA, Younan P, Blahnik-Fagan G, et al
     Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.
     Cell Rep Med. 2026;7:103021.
     PubMed    
     Abstract available
     
     

145. KIM HJ, Park W, Kim YS, Kim JS, et al
     Definitive Chemoradiotherapy Versus Radical Cystectomy for Small Cell Carcinoma of the Bladder: A Multicenter Retrospective Study.
     Clin Genitourin Cancer. 2026;24:102642.
     PubMed    
     Abstract available
     
     

146. RICCIARDI G, Ballato M, Tralongo P, Fiorentino V, et al
     Detection of FGFR Alterations in Urothelial Carcinoma: Current Diagnostic Methodologies, Technical Considerations and Future Perspectives.
     Clin Genitourin Cancer. 2026;24:102644.
     PubMed    
     Abstract available
     
     

147. ZAHIR M, Sanford DI, Doshi C, Alsyouf M, et al
     Evaluation, etiology, and management of gross hematuria following radical cystectomy and orthotopic neobladder.
     Urol Oncol. 2026;44:617-623.
     PubMed    
     Abstract available
     
     

148. LI J, Fredette J, Dhanikonda N, Jhaveri M, et al
     Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response.
     Clin Genitourin Cancer. 2026;24:102631.
     PubMed    
     Abstract available
     
     

149. SANAGAWA A, Kato H, Inoue T, Iwamoto T, et al
     Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
     Clin Genitourin Cancer. 2026;24:102617.
     PubMed    
     Abstract available
     
     

150. SCHNEIDEWIND L, Kranz J, Zengerling F, Neumann T, et al
     Sex-Specific Differences in Disease-Free, Progression-Free and Overall Survival Following Enfortumab Vedotin Therapy for Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
     Clin Genitourin Cancer. 2026;24:102611.
     PubMed    
     Abstract available
     
     

151. XING Q, Wei YB, Wang X, Hao HF, et al
     Comparison Study of Inverted-Nipple Ureteroneocystostomy and Direct Anastomosis in U-Shaped Orthotopic Neobladder Reconstruction.
     Ann Surg Oncol. 2026;33:9505-9516.
     PubMed    
     Abstract available
     
     

152. LI H, Akbari A, Schuler M, Salgado Esteves R, et al
     Giant Cell Urothelial Carcinoma: Morphometric Insights and Associations With Aggressive Clinical Features.
     Am J Surg Pathol. 2026;50:1184-1194.
     PubMed    
     Abstract available
     
     

153. IKEDA M, Ichikawa S, Ito S, Okumura K, et al
     Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Case Series.
     Chemotherapy. 2026;71:1-6.
     PubMed    
     Abstract available
     
     

154. BHANVADIA R, Bochner E, Jiang C, Hong AS, et al
     Identification of High-Performing Safety Net Hospitals for Radical Cystectomy: Implications for National Cancer Institute Cancer Center Partnership.
     JCO Oncol Pract. 2026;22:1572-1582.
     PubMed    
     Abstract available
     
     

155. MITTAL K, Mouw KW, Singh P
     Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic.
     JCO Oncol Pract. 2026;22:1508-1516.
     PubMed    
     Abstract available
     
     

156. LIU PT, Hsu WL, Chen TI, Chiang CJ, et al
     Association between cervical human papillomavirus infection and bladder cancer risk: A community-based cohort study.
     J Infect Public Health. 2026;19:103377.
     PubMed    
     Abstract available
     
     

157. LOPEZ M, Varela M, Ingold M, Lavaggi ML, et al
     Exploring MV14 as a nitric oxide-releasing strategy for bladder cancer: From synthesis to in vivo evaluation.
     Eur J Med Chem. 2026;320:119331.
     PubMed    
     Abstract available
     
     

158. LIU Y, Wu Y, Li J, Liu T, et al
     Nucleolin shields PTBP1 from autophagic degradation to sustain gemcitabine resistance in bladder cancer.
     Drug Resist Updat. 2026;90:101475.
     PubMed    
     Abstract available
     
     

159. OTA A, Kawai M, Himura R, Maruyama S, et al
     Enhanced NRF1-mediated proteasome bounce-back and nelfinavir-mediated bortezomib sensitization in gemcitabine/cisplatin-resistant bladder cancer cells.
     Biochem Biophys Res Commun. 2026;838:154629.
     PubMed    
     Abstract available
     
     

160. KIM M, Lee J, Shin YS, Nguyen TT, et al
     Oncological and perioperative outcomes of robot-assisted radical cystectomy: a real-world cohort study emulating a target trial.
     J Robot Surg. 2026;20:1023.
     PubMed    
     Abstract available
     
     

161. SIN C, Esen Akkas B, Vural Topuz O, Omak O, et al
     Diuretic-Enhanced Dual-Phase F-18 FDG PET/CT: A New Window Into Muscle-Invasive Bladder Cancer.
     World J Nucl Med. 2026;25:242-249.
     PubMed    
     Abstract available
     
     

162. LI X, Xing Y
     Re: Nielsen N.K, Hjort P.B, Hansen E.B, et al. Substaging and stratified treatment of T1 bladder cancer - a nationwide register?based study. Eur Urol Open Sci 2026;90:92?100.
     Eur Urol Open Sci. 2026;93:1-2.
     PubMed    
     
     
     

163. 
     Correction: Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.
     Front Oncol. 2026;16:1951323.
     PubMed    
     Abstract available
     
     

164. ZHANG X, Yu S, Liu S, Liu M, et al
     Phenanthrene Derivatives from Arundina graminifolia Inhibit the Migration and Proliferation of Human Bladder Cancer Cells.
     Anticancer Agents Med Chem. 2026.
     PubMed    
     Abstract available
     
     

165. COCA MEMBRIBES S, Berney DM, Beltran L, Nally E, et al
     HER1-HER4 expression and co-expression in advanced urothelial carcinoma.
     ESMO Open. 2026;11:108317.
     PubMed    
     Abstract available
     
     

166. CITAKKUL I, Arvas H, Karaoglan M, Koylu B, et al
     Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma.
     Curr Oncol. 2026;33:529.
     PubMed    
     Abstract available
     
     

167. SATASIYA V, Martinelli C, Pascal G, Ducci G, et al
     Functional characterization of FAM120A as a novel effector in the progranulin/EphA2 oncogenic axis in bladder cancer.
     J Exp Clin Cancer Res. 2026;45:205.
     PubMed    
     Abstract available
     
     

168. CICCARESE C, Occhipinti D, Troisi P, Shore ND, et al
     Safety profile of BCG with or without immunotherapy in non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis.
     ESMO Open. 2026;11:108529.
     PubMed    
     Abstract available
     
     

169. LIU J, Zhou Z, Zhang B, Liu R, et al
     GLG1 in cancer-associated fibroblasts promotes bladder cancer growth while limiting tumor apoptosis.
     Apoptosis. 2026;31:232.
     PubMed    
     Abstract available
     
     

170. LV Y, Yin Q, Li W, Deng L, et al
     Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes.
     Apoptosis. 2026;31:230.
     PubMed    
     Abstract available
     
     

171. YAMASAKI H, Hiramatsu H, Nakamichi J, Tei M, et al
     Antitumor effects of CEP32496 on urothelial carcinoma with BRAF mutation (V595E) in dogs.
     Can J Vet Res. 2026;90:121-129.
     PubMed    
     Abstract available
     
     

172. WEI X, Pei X, Yu S
     Tertiary lymphoid structures in urothelial carcinoma: bridging spatial architecture with therapeutic vulnerability in the post-BCG era.
     Front Immunol. 2026;17:1853633.
     PubMed    
     Abstract available
     
     

173. LI Y, Liu Y
     Ileum vs Colon for Neobladder Reconstruction After Radical Cystectomy: A Systematic Review and Meta-Analysis.
     Urol J. 2026;23:122-132.
     PubMed    
     Abstract available
     
     

174. HALALSHEH OM, Hulliel AF, Abualasal A, Aldeqes MI, et al
     Epidermoid Cyst of the Ureter Mimicking Recurrent Urothelial Carcinoma: A Case Report and Brief Literature Review.
     Am J Case Rep. 2026;27:e953801.
     PubMed    
     Abstract available
     
     

175. WANG X, Sun F, Hu J, Huang X, et al
     Associations of Anatomical Location and Reader Experience With the Diagnostic Performance of Multiparametric MRI-Derived VI-RADS for Muscle Invasive Bladder Cancer: A Multicenter Multireader Study.
     J Magn Reson Imaging. 2026 Sep 22. doi: 10.1002/jmri.70557.
     PubMed    
     Abstract available
     
     

176. UENO Y, Sofue K, Murakami T
     Editorial for "Associations of Anatomical Location and Reader Experience With the Diagnostic Performance of Multiparametric MRI-Derived VI-RADS for Muscle Invasive Bladder Cancer: A Multicenter Multireader Study".
     J Magn Reson Imaging. 2026 Sep 22. doi: 10.1002/jmri.70561.
     PubMed    
     
     
     

177. WIERENGA KA, Nieland IS, Liu Q, Rakers PRJ, et al
     E2F3 amplification primes bladder cancer cells for premature mitosis.
     Cancer Gene Ther. 2026 Sep 22. doi: 10.1038/s41417-026-01084.
     PubMed    
     Abstract available
     
     

178. PALE-GONZALEZ GA, Diaz-Fuentes H
     [Nested variant of urothelial carcinoma complicated with pulmonary lymphangitis carcinomatosis. Case report].
     Rev Med Inst Mex Seguro Soc. 2026;64:e7099.
     PubMed    
     Abstract available
     
     

179. DAVIS ID
     How Do I Treat the Very Elderly With Advanced Bladder Cancer as We Have so Many New Agents?
     JCO Oncol Pract. 2026 Sep 22:OP2601009. doi: 10.1200/OP-26-01009.
     PubMed    
     
     
     

180. SPIRITO L, Quintavalle C, Coppola P, Esposito M, et al
     Nanorobots and Exosomes: Driving the New Frontier for Bladder Tumors through Non-Coding RNAs.
     Oncol Res. 2026;34:8.
     PubMed    
     Abstract available
     
     

181. CHEN S, Gan X, Lv P, Meng Q, et al
     Comparison of Neoadjuvant Chemotherapy, Chemoimmunotherapy, and Upfront Radical Cystectomy in High-Risk Bladder Cancer: A Single-Center Retrospective Study.
     Oncol Res. 2026;34:16.
     PubMed    
     Abstract available
     
     

182. BAI Z, Song X, Sun J, Xiao W, et al
     Bladder Cancer Biomarkers: Recent Advances in Early Detection, Treatment Prediction, and Prognosis.
     Oncol Res. 2026;34:19.
     PubMed    
     Abstract available
     
     

183. LUTJE LS, Gruner C, Karsten CM, Merseburger AS, et al
     Complement tumor-crosstalk: the role of C5a receptors in urothelial carcinomas.
     Front Immunol. 2026;17:1885439.
     PubMed    
     Abstract available
     
     

184. ZAKHARIA Y, de Speville BD, Morales-Barrera R, Moreno I, et al
     Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma.
     J Immunother Cancer. 2026;14:e015178.
     PubMed    
     Abstract available
     
     

185. N P AM, Iyer RS, N PP, B JP, et al
     Task-agnostic explainable contrastive learning model for malignant cell detection in urine cytology.
     Biomed Phys Eng Express. 2026;12.
     PubMed    
     Abstract available
     
     

186. LEUNG EL
     A novel intervention strategy for bladder cancer targeting dual metabolic pathways-Unraveling the pleiotropic mechanisms of quercetin.
     Acta Pharm Sin B. 2026;16:6299-6300.
     PubMed    
     
     
     

187. ZHAI Z, Yang F, Feng R, Zhang H, et al
     Quercetin's antitumor effect in bladder cancer: Synergistic regulation of gut microbiota and l-serine metabolic pathway.
     Acta Pharm Sin B. 2026;16:5961-5979.
     PubMed    
     Abstract available
     
     

188. LI HZ, Zhu J, Weng GJ, Li JJ, et al
     Application of a magnetic biosensor based on novel cracker-shaped noble metal nanoparticles in dual-modal multidimensional detection of bladder cancer urinary biomarker HAase.
     Biosens Bioelectron. 2026;315:119246.
     PubMed    
     Abstract available
     
     

189. HE Y, Kong H, Zhang C, Li Y, et al
     Bladder Large Cell Neuroendocrine Carcinoma(LCNEC): A Case Report of Exfoliated Cytology and Pathological Characteristics.
     J Vis Exp. 2026;.
     PubMed    
     Abstract available
     
     

190. LIU P, Ma M, Wang S, Cao S, et al
     Ca(2)(+)/CaN-mediated NF-kappaB and NFAT activation drives arsenic-induced bladder epithelial pre-malignant behavior.
     Ecotoxicol Environ Saf. 2026;323:120728.
     PubMed    
     Abstract available
     
     

191. SUGIUCHI M, Tajima K, Ando R, Yamashita Y, et al
     Corneal stromal metastasis of urothelial carcinoma in a dog.
     Res Vet Sci. 2026;211:106374.
     PubMed    
     Abstract available
     
     

192. FAN Q, Fu Z, Zheng X, Wang G, et al
     The "perfect storm" in bladder oncology: a case of diverticular carcinoma with plasmacytoid features and its clinical ramifications.
     BMC Urol. 2026;26:223.
     PubMed    
     Abstract available
     
     

193. LIU C, Zhu Y, Liao Y, Yang X, et al
     A comparative study of robot-assisted laparoscopic radical cystectomy combined with urinary diversion: preoperative indicators and survival outcomes analysis at a single center.
     BMC Urol. 2026;26:225.
     PubMed    
     Abstract available
     
     

194. LI B, Li D, Deng N, Liu P, et al
     Prognostic Value of miR-145 in HER2-Positive Locally Advanced or Metastatic Urothelial Carcinoma Treated with Disitamab Vedotin.
     Cancer Invest. 2026;44:1008-1016.
     PubMed    
     Abstract available
     
     

195. HURLE R, Contieri R, Sormani F, Lazzeri M, et al
     Quality of life in patients on active surveillance for bladder cancer.
     BJU Int. 2026 Sep 9. doi: 10.1111/bju.70449.
     PubMed    
     
     
     

196. CONNOR MJ, Gopalakrishnan A, Mayor N, Bolton E, et al
     Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1-LaserComplete study).
     BJU Int. 2026;138:705-713.
     PubMed    
     Abstract available
     
     

197. CONTIERI R, van Rhijn BWG, Cathomas R, Lorch A, et al
     Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.
     BJU Int. 2026;138:558-564.
     PubMed    
     Abstract available
     
     

198. GABRIEL PE, Zhu A, Karim CG, Eraky A, et al
     Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.
     BJU Int. 2026;138:640-649.
     PubMed    
     Abstract available
     
     

199. ZUIDEMA A, Nijland L, van Megesen K, Vosjan MM, et al
     ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids.
     Br J Cancer. 2026 Aug 31. doi: 10.1038/s41416-026-03581.
     PubMed    
     Abstract available
     
     

200. SU X, Jin K, Zeng H, Liu Z, et al
     TP53 mutation-biased CD8(+) T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.
     Br J Cancer. 2026;135:1131-1139.
     PubMed    
     Abstract available
     
     

201. SONG B, Maurya H, Xia T, Tokuyama N, et al
     A stromal-immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study.
     Eur J Cancer. 2026;246:116979.
     PubMed    
     Abstract available
     
     

202. GIANNATEMPO P, Cerbone L, Calabro F
     Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, Begona P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Eng
     Eur Urol. 2026 Sep 18:S0302-2838(26)02368-7. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

203. ELALFY AM
     Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026
     Eur Urol. 2026 Sep 25:S0302-2838(26)02372-9. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

204. YANAGISAWA T, Matsukawa A, Iwatani K, Hayashida Y, et al
     Perioperative Safety and Long-Term Oncological Outcomes of En Bloc Resection of Bladder Tumor: A Multicenter Real-World Study of 668 Patients.
     Int J Urol. 2026;33:e70634.
     PubMed    
     Abstract available
     
     

205. OGAWA I, Narita T, Shinohara M, Kawashima Y, et al
     Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study.
     Int J Urol. 2026;33:e70636.
     PubMed    
     Abstract available
     
     

206. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
     Time-dependent effects of BCG plus immune checkpoint inhibitors in BCG-naive high-risk non-muscle-invasive bladder cancer: a reconstructed patient-level analysis.
     Int Urol Nephrol. 2026 Sep 4. doi: 10.1007/s11255-026-05373.
     PubMed    
     Abstract available
     
     

207. PETRELLI F, Ghidini A, Vavassori I, Rossitto M, et al
     Early versus deferred immunotherapy in urothelial carcinoma: a review of evidence and post-progression survival.
     Int Urol Nephrol. 2026;58:3969-3976.
     PubMed    
     Abstract available
     
     

208. ZAZA MM, ElAzab ME, Ebskharoun SF, Salem TAM, et al
     Evaluation of thulium laser endoscopic en bloc resection versus conventional trans-urethral en bloc resection of primary non-muscle invasive bladder cancer: a randomized controlled trial.
     Int Urol Nephrol. 2026 Sep 22. doi: 10.1007/s11255-026-05390.
     PubMed    
     Abstract available
     
     

209. CLARK PE, Holzbeierlein J, Chang SS, Djaladat H, et al
     2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline.
     J Urol. 2026 Sep 4:101097JU0000000000005280. doi: 10.1097/JU.0000000000005280.
     PubMed    
     Abstract available
     
     

210. JAYRAM G, Shore ND, Tyson M, Pieczonka C, et al
     PD09-07 Durvalumab in Combination with Bacillus Calmette-Guerin for Bacillus Calmette-Guerin-Naive, High-Risk Non-Muscle-Invasive Bladder Cancer: Primary Results from a US-Based, Phase IIIB, Open-Label, Single-Arm, Multicenter Study (PATAPSCO): Erratu
     J Urol. 2026;216:606.
     PubMed    
     
     
     

211. SHORE ND, Nishiyama H, Redorta JP, Krawczynski M, et al
     Durvalumab in Combination with Bacillus Calmette-Guerin Induction and Maintenance Therapy for Bacillus Calmette-Guerin-Naive, High-Risk Non-muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC: Erratum.
     J Urol. 2026;216:607.
     PubMed    
     
     
     

212. GARMAN TS, Lokeshwar S, Campbell J, Su ZT, et al
     Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.
     J Urol. 2026;216:540-550.
     PubMed    
     Abstract available
     
     

213. MATULEWICZ RS, Gold SA, Nicholson A, Candelieri-Surette D, et al
     Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration.
     J Urol. 2026 Sep 16:101097JU0000000000005312. doi: 10.1097/JU.0000000000005312.
     PubMed    
     Abstract available
     
     

214. NUSBAUM DJ, Gilbert SM, Li R
     Simpler risk stratification and new options for recurrent low-grade disease: 2026 update to the AUA/SUO non-muscle invasive bladder cancer guideline.
     J Urol. 2026 Sep 24:101097JU0000000000005323. doi: 10.1097/JU.0000000000005323.
     PubMed    
     
     
     

215. WEI H, Bai R, Liu J, Lyu L, et al
     POC1A promotes the proliferation, metastasis and stemness of bladder cancer by stabilizing BMI1 via USP7.
     Oncogene. 2026 Aug 31. doi: 10.1038/s41388-026-03973.
     PubMed    
     Abstract available
     
     

216. ZHAO Y, Xing Z, Wang M, Fu L, et al
     DHCR24(+) tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling.
     Oncogene. 2026 Aug 29. doi: 10.1038/s41388-026-03967.
     PubMed    
     Abstract available
     
     

217. QIAN L, Liu B, Zhang R, Zhang W, et al
     Epithelial tumor suppressor deletion promotes neuroendocrine differentiation in bladder cancer and reveals homoharringtonine as a candidate vulnerability.
     Oncogene. 2026 Sep 16. doi: 10.1038/s41388-026-03975.
     PubMed    
     Abstract available
     
     

218. CHUNG YH, Kim D
     [Expression of Concern] RIP kinase?mediated ROS production triggers XAF1 expression through activation of TAp73 in casticin?treated bladder cancer cells.
     Oncol Rep. 2026;56:186.
     PubMed    
     Abstract available
     
     

219. HJORT PB, Jensen JB, Ernst A
     Risk of Subsequent Recurrences and Progression in Non-muscle Invasive Bladder Cancer Patients With Early Recurrence.
     Urology. 2026 Sep 12:S0090-4295(26)00580-7. doi: 10.1016/j.urology.2026.
     PubMed    
     Abstract available
     
     

220. NAUMAN RW, Greer PA, Craig AW, Cotechini T, et al
     Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy.
     PLoS One. 2026;21:e0357950.
     PubMed    
     Abstract available
     
     

221. WU Y, Li G, Jiang L, Zhang C, et al
     A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study.
     PLoS One. 2026;21:e0358043.
     PubMed    
     Abstract available
     
     

222. XU S, Xie H, Yang Z, Ma Z, et al
     PAK4-targeting PROTAC inhibits bladder cancer cell proliferation.
     PLoS One. 2026;21:e0358561.
     PubMed    
     Abstract available